Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Luying Wang, Weili Gu, Xiao Zhang, Shihui Fu, Donger Zhang, Xin Guan, Hongchao Li & Aixia Ma. (2022) How the cost-effectiveness results change in the China health policy environment: an economic evaluation of glycopyrrolate/formoterol for the treatment of COPD. Journal of Medical Economics 25:1, pages 356-366.
Read now
Read now
Tanja Fens, Guiling Zhou, Maarten J. Postma, Eugène P. van Puijenbroek & Job F.M. van Boven. (2021) Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. Expert Opinion on Pharmacotherapy 22:7, pages 923-935.
Read now
Read now
Bhavesh Lakhotia, Ronan Mahon, Florian S Gutzwiller, Andriy Danyliv, Ivan Nikolaev & Praveen Thokala. (2020) Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 787-797.
Read now
Read now
Brian Godman, Holly McCabe, Trudy D Leong, Debjani Mueller, Antony P. Martin, Iris Hoxha, Julius C. Mwita, Godfrey Mutashambara Rwegerera, Amos Massele, Juliana de Oliveira Costa, Renata Cristina Rezende Macedo do Nascimento, Livia Lovato Pires de Lemos, Konstantin Tachkov, Petya Milushewa, Okwen Patrick, Loveline Lum Niba, Ott Laius, Israel Sefah, Suhaj Abdulsalim, Fatemeh Soleymani, Anastasia N Guantai, Loice Achieng, Margaret Oluka, Arianit Jakupi, Konstantīns Logviss, Mohamed Azmi Hassali, Dan Kibuule, Francis Kalemeera, Mwangana Mubita, Joseph Fadare, Olayinka O. Ogunleye, Zikria Saleem, Shazhad Hussain, Tomasz Bochenek, Ileana Mardare, Alian A. Alrasheedy, Jurij Furst, Dominik Tomek, Vanda Markovic-Pekovic, Enos M. Rampamba, Abubakr Alfadl, Adefolarin A Amu, Zinhle Matsebula, Thuy Nguyen Thi Phuong, Binh Nguyen Thanh, Aubrey Chichonyi Kalungia, Trust Zaranyika, Nyasha Masuka, Ioana D. Olaru, Janney Wale, Ruaraidh Hill, Amanj Kurdi, Angela Timoney, Stephen Campbell & Johanna C. Meyer. (2020) Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Review of Pharmacoeconomics & Outcomes Research 20:1, pages 1-26.
Read now
Read now
Articles from other publishers (5)
Safa Ahmadian, Don D Sin, Larry Lynd, Mark Harrison & Mohsen Sadatsafavi. (2022) Benefit–harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease. Thorax 77:11, pages 1079-1087.
Crossref
Crossref
A.L. Aguilar-Shea & C. Gallardo-Mayo. (2022) Revisión narrativa de la terapia inhalatoria en la EPOC. Medicina de Familia. SEMERGEN 48:3, pages 214-218.
Crossref
Crossref
Masato Muraki, Yuki Kunita, Ken Shirahase, Ryo Yamazaki, Soichiro Hanada, Hirochiyo Sawaguchi & Yuji Tohda. (2021) A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease. BMC Pulmonary Medicine 21:1.
Crossref
Crossref
Mario Cazzola & Maria Gabriella Matera. (2018) Rebuttal From Drs Cazzola and Matera. Chest 154:4, pages 751-752.
Crossref
Crossref
Safa Ahmadian, Donald Sin, Larry D. Lynd, Mark Harrison & Mohsen Sadatsafavi. (2021) A Benefit-Harm Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. SSRN Electronic Journal.
Crossref
Crossref